Navigation Links
Immune evasion common in many viruses, bacteria and parasites is uncommon in M. tuberculosis
Date:5/23/2010

(New York, NY, May 23, 2010): Scientists at NYU Langone Medical Center have discovered that the strategy of "immune evasion" common to many viruses, bacteria and parasites, is uncommon to M. tuberculosis where the antigens remain strikingly unchanged and homogenous. The study published in Nature Genetics on May 23, 2010, suggests that M. tuberculosis antigens do not mutate because they hope to be recognized by the body's immune system perhaps because the host immune mechanism that leads to the typical lung destruction and cough can contribute to the spread of the disease. This finding has the potential to change the direction of vaccine research and could result in a new focus on different targets of immune response to the bacteria.

"The finding that the tuberculosis bacterium acts completely differently from other pathogens is quite surprising and unexpected," said Joel Ernst, MD, director of the division of Infectious Diseases and Immunology at NYU Langone Medical Center in NYC and lead author of the study. "If you get infected with the influenza virus, for example, the body's immune system recognizes it and tends to eliminate it. In tuberculosis, our immune response doesn't get rid of it it tends to hold on to it for a while keeping the bacteria under partial control."

The immune system plays a key role in protecting the human body from invading pathogens. These pathogens have molecules known as antigens that are recognized by the immune system. However, many pathogens can evade immune recognition by varying their antigens. This study found that rather than "suffering" from being recognized, recognition of tuberculosis antigens actually benefit the bacteria and it is this recognition that helps the bacteria to be transmitted from person to person.

Tuberculosis is a major cause of death and disability worldwide, killing someone every 15 minutes. TB in New York City, and in the United States as a whole, is being driven by the global TB epidemic. In 2008, despite very aggressive and expensive public health efforts, there were 895 cases of TB and 11 cases of multidrug-resistant TB. Over 70 percent of all cases of TB in NYC in 2008 were among individuals born outside the United States, although people with TB can transmit the infection to anyone.

Tuberculosis is a major cause of death and disability worldwide, killing someone every 15 minutes. TB in New York City, and in the United States as a whole, is being driven by the global TB epidemic. In 2008, there were 895 cases of TB and 11 cases of multidrug-resistant TB. Over 70 percent of all cases of TB in NYC in 2008 were among individuals born outside the United States.

Of all the people who get the disease, 90 percent remain well while the immune system suppresses the disease. Approximately 10 percent of the people who get infected then transmit the disease. As a consequence of the emergence of drug resistance, the global epidemic of tuberculosis is worsening. Thus, new tools and strategies are urgently needed to combat this growing epidemic.

For this study, scientists used a novel high-throughput DNA sequencing method to analyze the whole genomes of 22 clinical strains of M. tuberculosis from different parts of the world. They then determined that the number of and type of mutations that occurred in antigens is much lower compared to other regions of the M. tuberculosis genome.


'/>"/>

Contact: Dorie Klissas
Dorie.klissas@nyumc.org
646-761-4724
NYU Langone Medical Center / New York University School of Medicine
Source:Eurekalert

Related biology news :

1. Immune system compromised during spaceflight, study finds
2. Cheese found to improve the immune response of the elderly
3. Directing immune traffic -- signposts to the lung
4. Brain tumor growth linked to lowered expression of hundreds of immune function genes
5. Study links 1976 swine flu shot to stronger immune response to 21st century pandemic flu
6. Investigational immune intervention slows brain shrinkage in Alzheimers patients
7. The immune systems guard against cancer
8. Study details machinery of immune protection against inflammatory diseases like colitis
9. Penn researchers identify immune cells that fight parasites may promote allergies and asthma
10. Vitamin D crucial to activating immune defenses
11. HIV vaccine strategy expands immune responses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
(Date:3/30/2017)... YORK , March 30, 2017 Trends, ... type (physiological and behavioral), by technology (fingerprint, AFIS, iris ... voice recognition, and others), by end use industry (government ... and immigration, financial and banking, and others), and by ... Europe , Asia Pacific , ...
Breaking Biology News(10 mins):
(Date:7/20/2017)... ... 2017 , ... Corista, a leader in integrated pathology solutions, ... 25, during the Association of Pathology Chairs’ Jubilee Meeting in Washington, DC. The ... Director of Pathology Informatics, will present “The Digital Pathology Experience at Johns Hopkins.” ...
(Date:7/20/2017)... ... July 20, 2017 , ... Corporate Directors Forum is recognizing six San Diego ... the Year Awards. , The awards will be presented Thursday, September 7th, from 6 ... directors who have made significantly positive contributions in the boardrooms of some of our ...
(Date:7/18/2017)... ... July 18, 2017 , ... Nanomedical Diagnostics, a cutting-edge ... the launch of a new NTA biosensor chip for use with its label-free ... kinetics of polyhistidine-tagged (His-tagged) molecules quickly and reliably. , “Recombinant proteins are ...
(Date:7/18/2017)... Switzerland (PRWEB) , ... July 18, 2017 , ... ... R&D, today announced that Merck, a leading science and technology company, has implemented ... innovative therapeutics for the therapeutic areas of Oncology, Immunology, and Neurodegenerative Diseases. , ...
Breaking Biology Technology: